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only partially. Second, as indicated previously [5],
the effect of the vaccine does not readily explain
the increased incidence of childhood empyema.
This complication has increased signiﬁcantly over
the last decade, even before the introduction of
HPCV in the UK and in areas of the USA, and has
been attributed mainly to Streptococcus pneumoniae
serotype 1 [6,7]. Finally, dramatic temporal chan-
ges in the epidemiology of IPD may occur follow-
ing the spread of clones of serotype 1. These clones
have caused outbreaks of IPD at the local, commu-
nity and nationwide levels, and have been gener-
ally associated with pulmonary disease and, to a
lesser extent, with meningitis [8,9].
In conclusion, more comprehensive surveil-
lance of a highly immunised population at the
national level, supported by molecular epidemi-
ological analyses, is needed before ﬁrm conclu-
sions regarding the impact of HPCV on IPD in
Spain can be reached.
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Identiﬁcation of a novel blaOXA-51 variant,
blaOXA-92, from a clinical isolate of
Acinetobacter baumannii
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Recent articles in CMI have described a novel
subgroup of OXA-type b-lactamases that appears
to be intrinsic in Acinetobacter baumannii [1)3].
These oxacillinases are chromosomally-encoded
and exhibit very poor hydrolytic activities against
carbapenems unless insertion sequence ISAba1 is
located upstream of the blaOXA-51-like gene [3,4].
Approximately 20 variants of the prototype
enzyme, OXA-51, have now been described. We
describe the identiﬁcation of a further novel OXA-
51 variant in A. baumannii that has been designa-
ted OXA-92.
An isolate of A. baumannii was recovered from
the blood culture of a patient hospitalised in a
Greek intensive care unit. MICs of imipenem and
meropenem were determined by the agar dilution
method, and the isolate was screened for blaOXA-51-
like genesusing the external primersOXA-69Aand
OXA-69B [5]. These primers amplify a 975-bp
product that includes the whole coding sequence
of the gene, which allows the different alleles to be
discriminated by sequence analysis. PCR was also
performed using primers speciﬁc for other carbap-
enemase-encoding genes (blaIMP, blaVIM, blaSIM,
blaOXA-23-like, blaOXA-24-like and blaOXA-58) [6,7].
Insertion sequence ISAba1was detected by PCR as
described previously [4], and the genetic element
carrying the blaOXA-51-like gene was investigated
by PCRmapping using ISAba1 forward and blaOXA-
51-like reverse primers.
The imipenem and meropenem MICs for the
isolate were 64 mg ⁄L and 8 mg ⁄L, respectively.
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The strain was multidrug-resistant, exhibiting
resistance to all other antimicrobial agents except
colistin. PCR screening was positive for blaOXA-51-
like and blaOXA-58 genes, but negative for blaIMP,
blaVIM, blaSIM, blaOXA-23-like and blaOXA-24-like
genes. Sequencing of the blaOXA-51-like amplicon
revealed a novel variant that had a G701C
transversion compared with the blaOXA-69 gene
sequence. This transversion resulted in a trypto-
phan to serine amino-acid substitution at position
234 (numbering according to OXA-69). The
mutation was outside the standard S-T-F-K,
S-X-I, Y-G-N and K-S-G oxacillinase motifs, and
possibly did not affect the hydrolytic activity of
the oxacillinase. Sequence alignment of the new
allele revealed 99% nucleotide and amino-acid
identity with blaOXA-69, 98% with blaOXA-65
and blaOXA-66, and 97% with the prototype
blaOXA-51 gene. This novel blaOXA-51 variant was
designated blaOXA-92 (GenBank accession number
DQ335566). The PCR for ISAba1 was positive,
but the PCR using the ISAba1 forward and
blaOXA-51-like reverse primers failed to yield an
amplicon.
The subgroup of class D carbapenemases com-
prising the OXA-51 variants was ﬁrst detected in
distinct clones of A. baumannii from Argentina
[1]. The number of alleles identiﬁed in this
subgroup seems to be increasing rapidly, so
that, to date, c. 20 b-lactamases belonging to this
subgroup have been identiﬁed among A. bau-
mannii isolates from Argentina, South Africa,
Hong Kong, Singapore and Europe [2,4,5,8,9].
The members of the cluster diverge by one to 15
amino-acid modiﬁcations, and these intrinsic
enzymes seem to represent a diverse collection
of b-lactamases in A. baumannii which, unlike
other class D carbapenemases, do not possess
the tyrosine to phenylalanine substitution in the
conserved Y-G-N motif of the class D protein
[10]. In the new blaOXA-92 allele, ISAba1 was not
found upstream of the blaOXA-92 structural gene,
implying that other mechanisms were most
likely associated with carbapenem resistance in
this isolate.
The blaOXA-92 gene differed from the original
blaOXA-69 gene by a single amino-acid mutation,
and these two genes should be regarded as
alleles derived from a common ancestor. This
observation is further supported by the fact that
the original blaOXA-69 gene and the closely
related blaOXA-66 gene have been detected pre-
viously in our hospitals [6,11]. Surveillance
studies are suggested in order to monitor the
dissemination of A. baumannii strains carrying
blaOXA-51 ⁄ 69 derivatives in hospitals in our region
and to determine their association with promo-
ter sequences.
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